In male mice, chronic treatment with the SSRI fluoxetine (Prozac) reduced the head-twitch response—a behavioral sign of 5-HT2A receptor activation—caused by the psychedelic DOI, while acute fluoxetine had no effect on DOI. The reduced response reversed after a 14-day discontinuation of fluoxetine. Acute fluoxetine also weakened the efficacy (but not potency) of psilocybin, indicating that SSRI-psychedelic interactions may differ depending on the specific psychedelic compound. These results suggest that a history of SSRI use can alter sensitivity to psychedelics in a compound-specific manner, with implications for psychedelic-assisted therapy in people taking SSRIs.
Most Louisiana psychiatrists surveyed are open to psilocybin's medical use if backed by regulation. 82% reported some knowledge of psilocybin; 86% believed it should be researched for medicinal value; 71% would prescribe it if proven beneficial for a patient's illness. 57% thought it should be a first-line treatment for certain conditions, while 73% believed it should be used only after other treatments failed. The 10.5% response rate limits generalizability. The findings suggest a need for educational programs on psychedelics to inform clinical decisions.
Early-career researchers in psychedelic science discuss the challenges and opportunities of building a career in this emerging field. They describe obstacles such as stigma, funding hurdles, and professional uncertainty alongside the potential for innovation and profound impact. The roundtable highlights the need for mentorship, interdisciplinary collaboration, and perseverance to advance the field and develop sustainable professional paths.